(Reuters) - By Lisa Richwine
GAITHERSBURG, Md., March 29 - Dendreon Corp. showed that its novel cancer therapy Provenge is reasonably safe and provided "substantial evidence" it benefits men with advanced prostate cancer, U.S. advisers ruled on Thursday.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment